Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Canaccord to hold a virtual forum » 08:24
11/19/20
11/19
08:24
11/19/20
08:24
AFIB

Acutus Medical

$24.91 /

-0.56 (-2.20%)

, APYX

Apyx Medical

$7.02 /

+0.04 (+0.57%)

, ATRC

AtriCure

$40.81 /

+0.46 (+1.14%)

, AWH

Aspira Women's Health

$4.66 /

+0.025 (+0.54%)

, AXGN

AxoGen

$15.16 /

-0.05 (-0.33%)

, CSTL

Castle Biosciences

$46.27 /

-2.05 (-4.24%)

, GNMK

GenMark

$13.97 /

+0.31 (+2.27%)

, GTH

Genetron

$11.35 /

-0.29 (-2.49%)

, INMD

InMode

$42.75 /

+0.16 (+0.38%)

, KIDS

OrthoPediatrics

$44.84 /

-1.55 (-3.34%)

, LMAT

LeMaitre

$38.21 /

-0.485 (-1.25%)

, LUNG

Pulmonx

$46.50 /

-0.07 (-0.15%)

, NARI

Inari Medical

$65.75 /

-2.08 (-3.07%)

, PEN

Penumbra

$258.60 /

-1.595 (-0.61%)

, PODD

Insulet

$259.27 /

-0.18 (-0.07%)

, RCEL

Avita Medical

$22.80 /

+0.09 (+0.40%)

, SIEN

Sientra

$4.83 /

+ (+0.00%)

, SPNE

SeaSpine

$14.01 /

-0.05 (-0.36%)

, TCMD

Tactile Systems

$43.95 /

+1 (+2.33%)

, TMDX

TransMedics

$14.17 /

-0.33 (-2.28%)

, XENT

Intersect ENT

$18.15 /

-0.46 (-2.47%)

, XGN

Exagen

$15.03 /

-0.11 (-0.73%)

2020 Medical Technologies…

2020 Medical Technologies & Diagnostics Virtual Forum will be held on November 19.

ShowHide Related Items >><<
XGN Exagen
$15.03 /

-0.11 (-0.73%)

XENT Intersect ENT
$18.15 /

-0.46 (-2.47%)

TMDX TransMedics
$14.17 /

-0.33 (-2.28%)

TCMD Tactile Systems
$43.95 /

+1 (+2.33%)

SPNE SeaSpine
$14.01 /

-0.05 (-0.36%)

SIEN Sientra
$4.83 /

+ (+0.00%)

RCEL Avita Medical
$22.80 /

+0.09 (+0.40%)

PODD Insulet
$259.27 /

-0.18 (-0.07%)

PEN Penumbra
$258.60 /

-1.595 (-0.61%)

NARI Inari Medical
$65.75 /

-2.08 (-3.07%)

LMAT LeMaitre
$38.21 /

-0.485 (-1.25%)

KIDS OrthoPediatrics
$44.84 /

-1.55 (-3.34%)

INMD InMode
$42.75 /

+0.16 (+0.38%)

GTH Genetron
$11.35 /

-0.29 (-2.49%)

GNMK GenMark
$13.97 /

+0.31 (+2.27%)

CSTL Castle Biosciences
$46.27 /

-2.05 (-4.24%)

AXGN AxoGen
$15.16 /

-0.05 (-0.33%)

AWH Aspira Women's Health
$4.66 /

+0.025 (+0.54%)

ATRC AtriCure
$40.81 /

+0.46 (+1.14%)

APYX Apyx Medical
$7.02 /

+0.04 (+0.57%)

AFIB Acutus Medical
$24.91 /

-0.56 (-2.20%)

AFIB Acutus Medical
$24.91 /

-0.56 (-2.20%)

08/31/20
Fly Intel: Top five analyst initiations
08/31/20 JPMorgan
Acutus Medical initiated with an Overweight at JPMorgan
08/31/20 William Blair
Acutus Medical initiated with an Outperform at William Blair
08/31/20 BTIG
Acutus Medical initiated with a Buy at BTIG
APYX Apyx Medical
$7.02 /

+0.04 (+0.57%)

06/22/20 Piper Sandler
Apyx Medical's expanded international sale 'important', says Piper Sandler
03/17/20 Piper Sandler
Apyx Medical price target lowered to $7 from $10 at Piper Sandler
01/13/20 JMP Securities
Apyx Medical shares likely to continue to appreciate, says JMP Securities
ATRC AtriCure
$40.81 /

+0.46 (+1.14%)

11/12/20 JPMorgan
JPMorgan a buyer of AtriCure ahead of 'major catalyst'
09/30/20 Piper Sandler
Piper Sandler 'highly' recommends five names in Medical Technology
07/29/20 SVB Leerink
AtriCure price target raised to $60 from $55 at SVB Leerink
07/29/20 Piper Sandler
AtriCure price target raised to $50 from $47 at Piper Sandler
AWH Aspira Women's Health
$4.66 /

+0.025 (+0.54%)

10/29/20 William Blair
Aspira Women's Health initiated with an Outperform at William Blair
AXGN AxoGen
$15.16 /

-0.05 (-0.33%)

10/22/20 Guggenheim
AxoGen initiated with a Buy at Guggenheim
06/16/20 Cantor Fitzgerald
AxoGen assumed with an Overweight at Cantor Fitzgerald
06/15/20 Cantor Fitzgerald
AxoGen assumed with an Overweight at Cantor Fitzgerald
05/07/20 Canaccord
AxoGen downgraded to Hold at Canaccord
CSTL Castle Biosciences
$46.27 /

-2.05 (-4.24%)

11/09/20 KeyBanc
Castle Biosciences initiated with an Overweight at KeyBanc
10/13/20 Canaccord
Castle Biosciences price target raised to $61 from $52 at Canaccord
09/25/20 SVB Leerink
Castle Biosciences price target raised to $57 from $50 at SVB Leerink
09/03/20 Canaccord
Castle Biosciences price target raised to $52 from $47 at Canaccord
GNMK GenMark
$13.97 /

+0.31 (+2.27%)

10/09/20 Canaccord
Execution positions GenMark for long-term success, says Canaccord
08/28/20 Canaccord
Hospital service channel shares weakness a buying opportunity, says Canaccord
08/05/20 Canaccord
GenMark price target raised to $22 from $20 at Canaccord
07/08/20 BTIG
GenMark price target raised to $18 from $14 at BTIG
GTH Genetron
$11.35 /

-0.29 (-2.49%)

09/30/20 Canaccord
Genetron China opportunity understated with current valuation, says Canaccord
08/03/20 Canaccord
Genetron outlook positive ahead of results, says Canaccord
07/14/20 BTIG
Genetron initiated with a Buy at BTIG
INMD InMode
$42.75 /

+0.16 (+0.38%)

10/21/20 Canaccord
InMode price target raised to $51 from $42 at Canaccord
10/13/20 Baird
InMode price target raised to $55 from $43 at Baird
02/19/20 Barclays
InMode price target raised to $48 from $45 at Barclays
01/28/20 Baird
InMode price target raised to $55 from $45 at Baird
KIDS OrthoPediatrics
$44.84 /

-1.55 (-3.34%)

10/07/20 BTIG
OrthoPediatrics price target raised to $57 from $54 at BTIG
08/06/20 Piper Sandler
Piper says OrthoPediatrics can win in 'more muted competitive environment'
08/06/20 Needham
OrthoPediatrics price target raised to $57 from $49 at Needham
06/23/20 Piper Sandler
OrthoPediatrics recovery better than expected, says Piper Sandler
LMAT LeMaitre
$38.21 /

-0.485 (-1.25%)

10/30/20 Barrington
LeMaitre price target raised to $46 from $36 at Barrington
10/28/20 Barrington
Varian Medical downgraded to Underperform from Outperform at Barrington
07/24/20 Lake Street
LeMaitre price target raised to $38 from $33 at Lake Street
05/04/20 Roth Capital
LeMaitre price target lowered to $28 from $32.50 at Roth Capital
LUNG Pulmonx
$46.50 /

-0.07 (-0.15%)

10/26/20 BofA
Pulmonx initiated with a Buy at BofA
10/26/20 Canaccord
Pulmonx initiated with a Buy at Canaccord
10/26/20 Morgan Stanley
Pulmonx initiated with an Equal Weight at Morgan Stanley
10/26/20 Stifel
Pulmonx initiated with a Buy at Stifel
NARI Inari Medical
$65.75 /

-2.08 (-3.07%)

11/18/20
Fly Intel: Top five analyst initiations
11/18/20 BTIG
Inari Medical initiated with a Buy at BTIG
11/13/20 SVB Leerink
Inari Medical price target raised to $90 from $80 at SVB Leerink
10/29/20 Morgan Stanley
Morgan Stanley upgrades Inari Medical on 'clear signs' of VTE inflection
PEN Penumbra
$258.60 /

-1.595 (-0.61%)

10/29/20 Canaccord
Penumbra price target raised to $292 from $253 at Canaccord
10/29/20 Wells Fargo
Penumbra price target raised to $265 from $255 at Wells Fargo
10/29/20 JPMorgan
JPMorgan ups Penumbra target, reiterates as top pick into 2021
PODD Insulet
$259.27 /

-0.18 (-0.07%)

11/05/20 Wells Fargo
Insulet price target raised to $266 from $250 at Wells Fargo
11/03/20 Piper Sandler
Clinical Trials update positive for Insulet, says Piper Sandler
10/16/20 Citi
Citi opens 'positive catalyst watch' on DexCom
08/11/20 Piper Sandler
Medtronic acquisition of Companion 'a smart decision,' says Piper Sandler
RCEL Avita Medical
$22.80 /

+0.09 (+0.40%)

08/27/20
Fly Intel: Top five analyst initiations
08/27/20 BofA
Avita Medical assumed with a Buy at BofA
07/09/20 BTIG
Avita Medical price target raised to $41 from $8 at BTIG
07/06/20 Oppenheimer
Avita Medical price target raised to $45 from $9 at Oppenheimer
SIEN Sientra
$4.83 /

+ (+0.00%)

10/08/20 Stifel
Stifel sees upside potential for Sientra after survey of aesthetics doctors
06/11/20 Maxim
Sientra price target raised to $8 from $5 at Maxim
03/12/20 Craig-Hallum
Sientra price target lowered to $9 from $14 at Craig-Hallum
03/12/20 SVB Leerink
Sientra price target lowered to $6.50 from $13 at SVB Leerink
SPNE SeaSpine
$14.01 /

-0.05 (-0.36%)

10/19/20 Stifel
SeaSpine initiated with a Buy at Stifel
10/06/20 Piper Sandler
SeaSpine remains 'must-own SMID-cap name,' says Piper Sandler
08/05/20 Piper Sandler
SeaSpine remains 'must own SMID name' at Piper Sandler
06/16/20 Cantor Fitzgerald
SeaSpine assumed with an Overweight at Cantor Fitzgerald
TCMD Tactile Systems
$43.95 /

+1 (+2.33%)

11/13/20 Oppenheimer
Tactile Systems upgraded to Outperform from Perform at Oppenheimer
11/13/20 Oppenheimer
Tactile Systems upgraded to Outperform from Perform at Oppenheimer
11/03/20 Piper Sandler
Tactile Systems shares still recommended after results at Piper Sandler
TMDX TransMedics
$14.17 /

-0.33 (-2.28%)

10/08/20
Fly Intel: Top five analyst downgrades
10/08/20 JPMorgan
TransMedics downgraded to Neutral on 'missed' execution at JPMorgan
10/08/20 JPMorgan
TransMedics downgraded to Neutral from Overweight at JPMorgan
09/29/20 Canaccord
TransMedics story intact despite OCS Heart delay, says Canaccord
XENT Intersect ENT
$18.15 /

-0.46 (-2.47%)

11/19/20 BTIG
Intersect ENT upgraded to Buy from Neutral at BTIG
11/02/20 Piper Sandler
Intersect ENT price target raised to $17 from $16 at Piper Sandler
10/22/20 Piper Sandler
Intersect ENT price target lowered to $16 from $17 at Piper Sandler
10/15/20 Piper Sandler
Intersect ENT shares may be pressured by below-consensus Q4, says Piper Sandler
XGN Exagen
$15.03 /

-0.11 (-0.73%)

11/09/20 KeyBanc
Exagen initiated with an Overweight at KeyBanc
10/07/20 BTIG
Exagen assumed with a Buy at BTIG
06/02/20 Cantor Fitzgerald
Exagen assumed with an Overweight at Cantor Fitzgerald
06/01/20 Cantor Fitzgerald
Exagen assumed with an Overweight at Cantor Fitzgerald
XGN Exagen
$15.03 /

-0.11 (-0.73%)

XENT Intersect ENT
$18.15 /

-0.46 (-2.47%)

TMDX TransMedics
$14.17 /

-0.33 (-2.28%)

TCMD Tactile Systems
$43.95 /

+1 (+2.33%)

SPNE SeaSpine
$14.01 /

-0.05 (-0.36%)

SIEN Sientra
$4.83 /

+ (+0.00%)

PODD Insulet
$259.27 /

-0.18 (-0.07%)

PEN Penumbra
$258.60 /

-1.595 (-0.61%)

NARI Inari Medical
$65.75 /

-2.08 (-3.07%)

LMAT LeMaitre
$38.21 /

-0.485 (-1.25%)

KIDS OrthoPediatrics
$44.84 /

-1.55 (-3.34%)

INMD InMode
$42.75 /

+0.16 (+0.38%)

GTH Genetron
$11.35 /

-0.29 (-2.49%)

GNMK GenMark
$13.97 /

+0.31 (+2.27%)

CSTL Castle Biosciences
$46.27 /

-2.05 (-4.24%)

AXGN AxoGen
$15.16 /

-0.05 (-0.33%)

ATRC AtriCure
$40.81 /

+0.46 (+1.14%)

APYX Apyx Medical
$7.02 /

+0.04 (+0.57%)

AFIB Acutus Medical
$24.91 /

-0.56 (-2.20%)

  • 01
    Oct
  • 06
    Aug
  • 25
    Jun
  • 18
    Jun
  • 19
    Jun
  • 28
    May
  • 27
    May
  • 22
    May
  • 13
    May
  • 12
    May
  • 07
    May
  • 08
    Jan
  • 11
    Dec
XENT Intersect ENT
$18.15 /

-0.46 (-2.47%)

PEN Penumbra
$258.60 /

-1.595 (-0.61%)

ATRC AtriCure
$40.81 /

+0.46 (+1.14%)

XENT Intersect ENT
$18.15 /

-0.46 (-2.47%)

TMDX TransMedics
$14.17 /

-0.33 (-2.28%)

SPNE SeaSpine
$14.01 /

-0.05 (-0.36%)

PODD Insulet
$259.27 /

-0.18 (-0.07%)

PEN Penumbra
$258.60 /

-1.595 (-0.61%)

NARI Inari Medical
$65.75 /

-2.08 (-3.07%)

LUNG Pulmonx
$46.50 /

-0.07 (-0.15%)

LMAT LeMaitre
$38.21 /

-0.485 (-1.25%)

KIDS OrthoPediatrics
$44.84 /

-1.55 (-3.34%)

GTH Genetron
$11.35 /

-0.29 (-2.49%)

GNMK GenMark
$13.97 /

+0.31 (+2.27%)

CSTL Castle Biosciences
$46.27 /

-2.05 (-4.24%)

AXGN AxoGen
$15.16 /

-0.05 (-0.33%)

APYX Apyx Medical
$7.02 /

+0.04 (+0.57%)

AFIB Acutus Medical
$24.91 /

-0.56 (-2.20%)

TMDX TransMedics
$14.17 /

-0.33 (-2.28%)

NARI Inari Medical
$65.75 /

-2.08 (-3.07%)

CSTL Castle Biosciences
$46.27 /

-2.05 (-4.24%)

AWH Aspira Women's Health
$4.66 /

+0.025 (+0.54%)

Conference/Events
Jefferies to hold a virtual conference » 04:55
11/19/20
11/19
04:55
11/19/20
04:55
MRNA

Moderna

$88.90 /

-4.225 (-4.54%)

, IMGN

ImmunoGen

$5.75 /

-0.035 (-0.61%)

, ESPR

Esperion

$29.18 /

-0.95 (-3.15%)

, CRL

Charles River

$234.11 /

-2.205 (-0.93%)

, AXGN

AxoGen

$15.16 /

-0.05 (-0.33%)

, INMD

InMode

$42.75 /

+0.16 (+0.38%)

, PRTA

Prothena

$12.10 /

-0.24 (-1.94%)

, SYNH

Syneos Health

$63.21 /

-0.24 (-0.38%)

, RDNT

RadNet

$18.19 /

-0.75 (-3.96%)

, OPNT

Opiant Pharmaceuticals

$7.95 /

+0.2 (+2.58%)

, FGEN

FibroGen

$41.56 /

-2.58 (-5.85%)

, MGLN

Magellan Health

$82.25 /

-2.47 (-2.92%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, CARA

Cara Therapeutics

$15.66 /

-0.53 (-3.27%)

, IVA

Inventiva

$14.00 /

+ (+0.00%)

, ITOS

iTeos Therapeutics

$25.09 /

+1.14 (+4.76%)

, CLBS

Caladrius

$1.44 /

-0.055 (-3.68%)

, ALNA

Allena Pharmaceuticals

$1.37 /

-0.07 (-4.86%)

, SEEL

Seelos Therapeutics

$0.78 /

-0.0296 (-3.65%)

, SMMNY

Siemens Healthineers

$0.00 /

+ (+0.00%)

, CNCE

Concert Pharmaceuticals

$10.82 /

-0.23 (-2.08%)

Virtual Healthcare…

Virtual Healthcare Conference will be held on November 17-19.

ShowHide Related Items >><<
SYNH Syneos Health
$63.21 /

-0.24 (-0.38%)

SMMNY Siemens Healthineers
$0.00 /

+ (+0.00%)

SEEL Seelos Therapeutics
$0.78 /

-0.0296 (-3.65%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RDNT RadNet
$18.19 /

-0.75 (-3.96%)

PRTA Prothena
$12.10 /

-0.24 (-1.94%)

OPNT Opiant Pharmaceuticals
$7.95 /

+0.2 (+2.58%)

MRNA Moderna
$88.90 /

-4.225 (-4.54%)

MGLN Magellan Health
$82.25 /

-2.47 (-2.92%)

IVA Inventiva
$14.00 /

+ (+0.00%)

ITOS iTeos Therapeutics
$25.09 /

+1.14 (+4.76%)

INMD InMode
$42.75 /

+0.16 (+0.38%)

IMGN ImmunoGen
$5.75 /

-0.035 (-0.61%)

FGEN FibroGen
$41.56 /

-2.58 (-5.85%)

ESPR Esperion
$29.18 /

-0.95 (-3.15%)

CRL Charles River
$234.11 /

-2.205 (-0.93%)

CNCE Concert Pharmaceuticals
$10.82 /

-0.23 (-2.08%)

CLBS Caladrius
$1.44 /

-0.055 (-3.68%)

CARA Cara Therapeutics
$15.66 /

-0.53 (-3.27%)

AXGN AxoGen
$15.16 /

-0.05 (-0.33%)

ALNA Allena Pharmaceuticals
$1.37 /

-0.07 (-4.86%)

MRNA Moderna
$88.90 /

-4.225 (-4.54%)

11/17/20 Benchmark
Inovio on 'top-10 vaccine contenders list,' says Benchmark
11/17/20 Maxim
Co-Diagnostics price target lowered to $20 from $30 at Maxim
11/17/20 Roth Capital
Inovio downgraded to Sell at Roth Capital on increased competition
11/17/20 Redburn
Moderna initiated with a Sell at Redburn
IMGN ImmunoGen
$5.75 /

-0.035 (-0.61%)

10/26/20 H.C. Wainwright
ImmunoGen assumed with a Buy at H.C. Wainwright
10/19/20 Piper Sandler
Greater China partnership 'very favorable' for ImmunoGen, says Piper Sandler
10/05/20 Piper Sandler
Piper says r/r BPDCN revenue opportunity for ImmunoGen's 632 'an open question'
10/02/20 Guggenheim
ImmunoGen upgraded to Buy from Neutral at Guggenheim
ESPR Esperion
$29.18 /

-0.95 (-3.15%)

11/10/20 Credit Suisse
Esperion upgraded to Outperform from Neutral at Credit Suisse
09/29/20 JPMorgan
Esperion resumed with an Underweight at JPMorgan
08/10/20 Credit Suisse
Esperion downgraded to Neutral from Outperform at Credit Suisse
05/07/20 Citi
Esperion price target raised to $56 from $46 at Citi
CRL Charles River
$234.11 /

-2.205 (-0.93%)

11/03/20 Truist
Charles River price target raised to $256 from $237 at Truist
10/30/20 Deutsche Bank
Charles River price target raised to $250 from $235 at Deutsche Bank
09/14/20 Argus
Charles River price target raised to $235 from $190 at Argus
09/10/20
Fly Intel: Top five analyst upgrades
AXGN AxoGen
$15.16 /

-0.05 (-0.33%)

10/22/20 Guggenheim
AxoGen initiated with a Buy at Guggenheim
06/16/20 Cantor Fitzgerald
AxoGen assumed with an Overweight at Cantor Fitzgerald
06/15/20 Cantor Fitzgerald
AxoGen assumed with an Overweight at Cantor Fitzgerald
05/07/20 Canaccord
AxoGen downgraded to Hold at Canaccord
INMD InMode
$42.75 /

+0.16 (+0.38%)

10/21/20 Canaccord
InMode price target raised to $51 from $42 at Canaccord
10/13/20 Baird
InMode price target raised to $55 from $43 at Baird
02/19/20 Barclays
InMode price target raised to $48 from $45 at Barclays
01/28/20 Baird
InMode price target raised to $55 from $45 at Baird
PRTA Prothena
$12.10 /

-0.24 (-1.94%)

10/21/20 Cantor Fitzgerald
Prothena price target raised to $24 from $20 at Cantor Fitzgerald
07/09/20 Oppenheimer
Prothena upgraded to Outperform at Oppenheimer
07/09/20 Oppenheimer
Prothena upgraded to Outperform from Perform at Oppenheimer
11/19/19 Evercore ISI
Prothena upgraded to Outperform on valuation at Evercore ISI
SYNH Syneos Health
$63.21 /

-0.24 (-0.38%)

10/06/20 Mizuho
Syneos Health upgraded to Buy on attractive entry point at Mizuho
10/06/20 Mizuho
Syneos Health upgraded to Buy from Neutral at Mizuho
10/01/20 Goldman Sachs
Syneos Health upgraded to Buy from Neutral at Goldman Sachs
08/12/20 Truist
Syneos Health price target raised to $80 from $74 at Truist
RDNT RadNet
$18.19 /

-0.75 (-3.96%)

09/03/20 Clarus
Akumin can re-rate as Nasdaq listing raises U.S. awareness, says Clarus
OPNT Opiant Pharmaceuticals
$7.95 /

+0.2 (+2.58%)

FGEN FibroGen
$41.56 /

-2.58 (-5.85%)

10/26/20 Raymond James
FibroGen initiated with an Underperform at Raymond James
10/26/20 Raymond James
FibroGen initiated with an Underperform at Raymond James
10/23/20 Stifel
FibroGen safety data mitigates concerns of roxadustat black box, says Stifel
09/04/20 Stifel
FibroGen's roxadustat can be 'dominant leader' as competitor fades, says Stifel
MGLN Magellan Health
$82.25 /

-2.47 (-2.92%)

11/13/20
Fly Intel: Top five analyst upgrades
11/13/20 Stephens
Magellan Health upgraded to Overweight from Equal Weight at Stephens
RHHBY Roche
$0.00 /

+ (+0.00%)

11/11/20 Truist
Opthea initiated with a Buy at Truist
10/16/20 UBS
Roche price target lowered to CHF 370 from CHF 390 at UBS
10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
09/29/20 Berenberg
Roche initiated with a Hold at Berenberg
CARA Cara Therapeutics
$15.66 /

-0.53 (-3.27%)

10/20/20 H.C. Wainwright
Cara deal with 'perfect partner' Vifor boosts confidence at H.C. Wainwright
04/22/20 Cantor Fitzgerald
Cara Therapeutics price target raised to $34 from $26 at Cantor Fitzgerald
04/21/20 H.C. Wainwright
Cara Therapeutics price target raised to $33 from $30 at H.C. Wainwright
01/10/20 Stifel
Cara Therapeutics named a BioPharma top pick for 2020 at Stifel
IVA Inventiva
$14.00 /

+ (+0.00%)

10/13/20 Roth Capital
Roth backs Buy on Inventiva after Lanifibranor given breakthrough designation
08/17/20 H.C. Wainwright
Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright
08/05/20
Fly Intel: Top five analyst initiations
08/05/20 Roth Capital
Inventiva initiated with a Buy at Roth Capital
ITOS iTeos Therapeutics
$25.09 /

+1.14 (+4.76%)

10/07/20 Baird
iTeos Therapeutics initiated with an Outperform at Baird
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
09/01/20 Piper Sandler
iTeos Therapeutics heading for 'catalyst rich stretch', says Piper Sandler
08/18/20 SVB Leerink
SVB Leerink bullish on iTeos Therapeutics, initiates with an Outperform
CLBS Caladrius
$1.44 /

-0.055 (-3.68%)

05/22/20 Brookline
Caladrius initiated with a Buy at Brookline
05/18/20 Dawson James
Caladrius downgraded to Neutral from Buy at Dawson James
ALNA Allena Pharmaceuticals
$1.37 /

-0.07 (-4.86%)

10/01/20 B. Riley Securities
Allena Pharmaceuticals price target raised to $5 from $4 at B. Riley Securities
06/01/20 H.C. Wainwright
Allena Pharmaceuticals initiated with a Buy at H.C. Wainwright
03/18/20 Roth Capital
Allena Pharmaceuticals price target lowered to $11 from $31 at Roth Capital
02/12/20 Roth Capital
Streamlining makes Allena URIROX-2 path clear, says Roth Capital
SEEL Seelos Therapeutics
$0.78 /

-0.0296 (-3.65%)

09/09/20 Roth Capital
Seelos Therapeutics shares 'substantially undervalued,' says Roth Capital
06/23/20 Roth Capital
Seelos Therapeutics price target raised to $12 from $8 Roth Capital
SMMNY Siemens Healthineers
$0.00 /

+ (+0.00%)

11/10/20 Credit Suisse
Siemens Healthineers price target raised to EUR 44 from EUR 43 at Credit Suisse
10/28/20 Barrington
Varian Medical downgraded to Underperform from Outperform at Barrington
10/26/20 RBC Capital
Siemens Healthineers price target lowered to EUR 42 from EUR 45 at RBC Capital
10/06/20 Deutsche Bank
Siemens Healthineers price target lowered to EUR 39 at Deutsche Bank
CNCE Concert Pharmaceuticals
$10.82 /

-0.23 (-2.08%)

11/04/20 JMP Securities
Concert Pharmaceuticals resumed with an Outperform at JMP Securities
03/30/20
Fly Intel: Top five analyst initiations
03/30/20 Jefferies
Concert Pharmaceuticals initiated with a Buy at Jefferies
02/27/20 Stifel
Concert Pharmaceuticals price target raised to $11 from $8 at Stifel
SYNH Syneos Health
$63.21 /

-0.24 (-0.38%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RDNT RadNet
$18.19 /

-0.75 (-3.96%)

PRTA Prothena
$12.10 /

-0.24 (-1.94%)

OPNT Opiant Pharmaceuticals
$7.95 /

+0.2 (+2.58%)

MRNA Moderna
$88.90 /

-4.225 (-4.54%)

MGLN Magellan Health
$82.25 /

-2.47 (-2.92%)

ITOS iTeos Therapeutics
$25.09 /

+1.14 (+4.76%)

INMD InMode
$42.75 /

+0.16 (+0.38%)

IMGN ImmunoGen
$5.75 /

-0.035 (-0.61%)

FGEN FibroGen
$41.56 /

-2.58 (-5.85%)

ESPR Esperion
$29.18 /

-0.95 (-3.15%)

CRL Charles River
$234.11 /

-2.205 (-0.93%)

CNCE Concert Pharmaceuticals
$10.82 /

-0.23 (-2.08%)

CLBS Caladrius
$1.44 /

-0.055 (-3.68%)

CARA Cara Therapeutics
$15.66 /

-0.53 (-3.27%)

AXGN AxoGen
$15.16 /

-0.05 (-0.33%)

ALNA Allena Pharmaceuticals
$1.37 /

-0.07 (-4.86%)

  • 16
    Sep
  • 24
    Jul
  • 10
    Jul
  • 19
    May
  • 12
    Mar
  • 11
    Feb
  • 12
    Feb
  • 28
    Jan
  • 21
    Jan
RHHBY Roche
$0.00 /

+ (+0.00%)

MRNA Moderna
$88.90 /

-4.225 (-4.54%)

SYNH Syneos Health
$63.21 /

-0.24 (-0.38%)

SMMNY Siemens Healthineers
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

MRNA Moderna
$88.90 /

-4.225 (-4.54%)

IVA Inventiva
$14.00 /

+ (+0.00%)

ITOS iTeos Therapeutics
$25.09 /

+1.14 (+4.76%)

IMGN ImmunoGen
$5.75 /

-0.035 (-0.61%)

FGEN FibroGen
$41.56 /

-2.58 (-5.85%)

ESPR Esperion
$29.18 /

-0.95 (-3.15%)

CARA Cara Therapeutics
$15.66 /

-0.53 (-3.27%)

AXGN AxoGen
$15.16 /

-0.05 (-0.33%)

MRNA Moderna
$88.90 /

-4.225 (-4.54%)

FGEN FibroGen
$41.56 /

-2.58 (-5.85%)

ESPR Esperion
$29.18 /

-0.95 (-3.15%)

Conference/Events
Jefferies to hold a virtual conference » 04:55
11/18/20
11/18
04:55
11/18/20
04:55
MRNA

Moderna

$93.12 /

-4.88 (-4.98%)

, IMGN

ImmunoGen

$5.78 /

+0.03 (+0.52%)

, ESPR

Esperion

$30.13 /

+0.02 (+0.07%)

, CRL

Charles River

$236.30 /

-1.56 (-0.66%)

, AXGN

AxoGen

$15.29 /

+0.18 (+1.19%)

, INMD

InMode

$42.61 /

+0.8 (+1.91%)

, PRTA

Prothena

$12.34 /

-0.03 (-0.24%)

, SYNH

Syneos Health

$63.45 /

-0.37 (-0.58%)

, RDNT

RadNet

$18.94 /

-0.05 (-0.26%)

, OPNT

Opiant Pharmaceuticals

$7.78 /

-0.02 (-0.26%)

, FGEN

FibroGen

$44.14 /

+1.12 (+2.60%)

, MGLN

Magellan Health

$84.72 /

-0.64 (-0.75%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, CARA

Cara Therapeutics

$16.19 /

+0.5 (+3.19%)

, IVA

Inventiva

$14.00 /

+0.175 (+1.27%)

, ITOS

iTeos Therapeutics

$23.95 /

-0.08 (-0.33%)

, CLBS

Caladrius

$1.50 /

-0.005 (-0.33%)

, ALNA

Allena Pharmaceuticals

$1.43 /

-0.15 (-9.49%)

, SEEL

Seelos Therapeutics

$0.81 /

-0.0119 (-1.45%)

, SMMNY

Siemens Healthineers

$0.00 /

+ (+0.00%)

, CNCE

Concert Pharmaceuticals

$11.04 /

+0.03 (+0.27%)

Virtual Healthcare…

Virtual Healthcare Conference will be held on November 17-19.

ShowHide Related Items >><<
SYNH Syneos Health
$63.45 /

-0.37 (-0.58%)

SMMNY Siemens Healthineers
$0.00 /

+ (+0.00%)

SEEL Seelos Therapeutics
$0.81 /

-0.0119 (-1.45%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RDNT RadNet
$18.94 /

-0.05 (-0.26%)

PRTA Prothena
$12.34 /

-0.03 (-0.24%)

OPNT Opiant Pharmaceuticals
$7.78 /

-0.02 (-0.26%)

MRNA Moderna
$93.12 /

-4.88 (-4.98%)

MGLN Magellan Health
$84.72 /

-0.64 (-0.75%)

IVA Inventiva
$14.00 /

+0.175 (+1.27%)

ITOS iTeos Therapeutics
$23.95 /

-0.08 (-0.33%)

INMD InMode
$42.61 /

+0.8 (+1.91%)

IMGN ImmunoGen
$5.78 /

+0.03 (+0.52%)

FGEN FibroGen
$44.14 /

+1.12 (+2.60%)

ESPR Esperion
$30.13 /

+0.02 (+0.07%)

CRL Charles River
$236.30 /

-1.56 (-0.66%)

CNCE Concert Pharmaceuticals
$11.04 /

+0.03 (+0.27%)

CLBS Caladrius
$1.50 /

-0.005 (-0.33%)

CARA Cara Therapeutics
$16.19 /

+0.5 (+3.19%)

AXGN AxoGen
$15.29 /

+0.18 (+1.19%)

ALNA Allena Pharmaceuticals
$1.43 /

-0.15 (-9.49%)

MRNA Moderna
$93.12 /

-4.88 (-4.98%)

11/17/20 Benchmark
Inovio on 'top-10 vaccine contenders list,' says Benchmark
11/17/20 Maxim
Co-Diagnostics price target lowered to $20 from $30 at Maxim
11/17/20 Roth Capital
Inovio downgraded to Sell at Roth Capital on increased competition
11/17/20 Redburn
Moderna initiated with a Sell at Redburn
IMGN ImmunoGen
$5.78 /

+0.03 (+0.52%)

10/26/20 H.C. Wainwright
ImmunoGen assumed with a Buy at H.C. Wainwright
10/19/20 Piper Sandler
Greater China partnership 'very favorable' for ImmunoGen, says Piper Sandler
10/05/20 Piper Sandler
Piper says r/r BPDCN revenue opportunity for ImmunoGen's 632 'an open question'
10/02/20 Guggenheim
ImmunoGen upgraded to Buy from Neutral at Guggenheim
ESPR Esperion
$30.13 /

+0.02 (+0.07%)

11/10/20 Credit Suisse
Esperion upgraded to Outperform from Neutral at Credit Suisse
09/29/20 JPMorgan
Esperion resumed with an Underweight at JPMorgan
08/10/20 Credit Suisse
Esperion downgraded to Neutral from Outperform at Credit Suisse
05/07/20 Citi
Esperion price target raised to $56 from $46 at Citi
CRL Charles River
$236.30 /

-1.56 (-0.66%)

11/03/20 Truist
Charles River price target raised to $256 from $237 at Truist
10/30/20 Deutsche Bank
Charles River price target raised to $250 from $235 at Deutsche Bank
09/14/20 Argus
Charles River price target raised to $235 from $190 at Argus
09/10/20
Fly Intel: Top five analyst upgrades
AXGN AxoGen
$15.29 /

+0.18 (+1.19%)

10/22/20 Guggenheim
AxoGen initiated with a Buy at Guggenheim
06/16/20 Cantor Fitzgerald
AxoGen assumed with an Overweight at Cantor Fitzgerald
06/15/20 Cantor Fitzgerald
AxoGen assumed with an Overweight at Cantor Fitzgerald
05/07/20 Canaccord
AxoGen downgraded to Hold at Canaccord
INMD InMode
$42.61 /

+0.8 (+1.91%)

10/21/20 Canaccord
InMode price target raised to $51 from $42 at Canaccord
10/13/20 Baird
InMode price target raised to $55 from $43 at Baird
02/19/20 Barclays
InMode price target raised to $48 from $45 at Barclays
01/28/20 Baird
InMode price target raised to $55 from $45 at Baird
PRTA Prothena
$12.34 /

-0.03 (-0.24%)

10/21/20 Cantor Fitzgerald
Prothena price target raised to $24 from $20 at Cantor Fitzgerald
07/09/20 Oppenheimer
Prothena upgraded to Outperform at Oppenheimer
07/09/20 Oppenheimer
Prothena upgraded to Outperform from Perform at Oppenheimer
11/19/19 Evercore ISI
Prothena upgraded to Outperform on valuation at Evercore ISI
SYNH Syneos Health
$63.45 /

-0.37 (-0.58%)

10/06/20 Mizuho
Syneos Health upgraded to Buy on attractive entry point at Mizuho
10/06/20 Mizuho
Syneos Health upgraded to Buy from Neutral at Mizuho
10/01/20 Goldman Sachs
Syneos Health upgraded to Buy from Neutral at Goldman Sachs
08/12/20 Truist
Syneos Health price target raised to $80 from $74 at Truist
RDNT RadNet
$18.94 /

-0.05 (-0.26%)

09/03/20 Clarus
Akumin can re-rate as Nasdaq listing raises U.S. awareness, says Clarus
OPNT Opiant Pharmaceuticals
$7.78 /

-0.02 (-0.26%)

FGEN FibroGen
$44.14 /

+1.12 (+2.60%)

10/26/20 Raymond James
FibroGen initiated with an Underperform at Raymond James
10/26/20 Raymond James
FibroGen initiated with an Underperform at Raymond James
10/23/20 Stifel
FibroGen safety data mitigates concerns of roxadustat black box, says Stifel
09/04/20 Stifel
FibroGen's roxadustat can be 'dominant leader' as competitor fades, says Stifel
MGLN Magellan Health
$84.72 /

-0.64 (-0.75%)

11/13/20
Fly Intel: Top five analyst upgrades
11/13/20 Stephens
Magellan Health upgraded to Overweight from Equal Weight at Stephens
RHHBY Roche
$0.00 /

+ (+0.00%)

11/11/20 Truist
Opthea initiated with a Buy at Truist
10/16/20 UBS
Roche price target lowered to CHF 370 from CHF 390 at UBS
10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
09/29/20 Berenberg
Roche initiated with a Hold at Berenberg
CARA Cara Therapeutics
$16.19 /

+0.5 (+3.19%)

10/20/20 H.C. Wainwright
Cara deal with 'perfect partner' Vifor boosts confidence at H.C. Wainwright
04/22/20 Cantor Fitzgerald
Cara Therapeutics price target raised to $34 from $26 at Cantor Fitzgerald
04/21/20 H.C. Wainwright
Cara Therapeutics price target raised to $33 from $30 at H.C. Wainwright
01/10/20 Stifel
Cara Therapeutics named a BioPharma top pick for 2020 at Stifel
IVA Inventiva
$14.00 /

+0.175 (+1.27%)

10/13/20 Roth Capital
Roth backs Buy on Inventiva after Lanifibranor given breakthrough designation
08/17/20 H.C. Wainwright
Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright
08/05/20
Fly Intel: Top five analyst initiations
08/05/20 Roth Capital
Inventiva initiated with a Buy at Roth Capital
ITOS iTeos Therapeutics
$23.95 /

-0.08 (-0.33%)

10/07/20 Baird
iTeos Therapeutics initiated with an Outperform at Baird
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
09/01/20 Piper Sandler
iTeos Therapeutics heading for 'catalyst rich stretch', says Piper Sandler
08/18/20 SVB Leerink
SVB Leerink bullish on iTeos Therapeutics, initiates with an Outperform
CLBS Caladrius
$1.50 /

-0.005 (-0.33%)

05/22/20 Brookline
Caladrius initiated with a Buy at Brookline
05/18/20 Dawson James
Caladrius downgraded to Neutral from Buy at Dawson James
ALNA Allena Pharmaceuticals
$1.43 /

-0.15 (-9.49%)

10/01/20 B. Riley Securities
Allena Pharmaceuticals price target raised to $5 from $4 at B. Riley Securities
06/01/20 H.C. Wainwright
Allena Pharmaceuticals initiated with a Buy at H.C. Wainwright
03/18/20 Roth Capital
Allena Pharmaceuticals price target lowered to $11 from $31 at Roth Capital
02/12/20 Roth Capital
Streamlining makes Allena URIROX-2 path clear, says Roth Capital
SEEL Seelos Therapeutics
$0.81 /

-0.0119 (-1.45%)

09/09/20 Roth Capital
Seelos Therapeutics shares 'substantially undervalued,' says Roth Capital
06/23/20 Roth Capital
Seelos Therapeutics price target raised to $12 from $8 Roth Capital
11/18/19 H.C. Wainwright
Seelos Therapeutics price target lowered to $2 from $4 at H.C. Wainwright
SMMNY Siemens Healthineers
$0.00 /

+ (+0.00%)

11/10/20 Credit Suisse
Siemens Healthineers price target raised to EUR 44 from EUR 43 at Credit Suisse
10/28/20 Barrington
Varian Medical downgraded to Underperform from Outperform at Barrington
10/26/20 RBC Capital
Siemens Healthineers price target lowered to EUR 42 from EUR 45 at RBC Capital
10/06/20 Deutsche Bank
Siemens Healthineers price target lowered to EUR 39 at Deutsche Bank
CNCE Concert Pharmaceuticals
$11.04 /

+0.03 (+0.27%)

11/04/20 JMP Securities
Concert Pharmaceuticals resumed with an Outperform at JMP Securities
03/30/20
Fly Intel: Top five analyst initiations
03/30/20 Jefferies
Concert Pharmaceuticals initiated with a Buy at Jefferies
02/27/20 Stifel
Concert Pharmaceuticals price target raised to $11 from $8 at Stifel
SYNH Syneos Health
$63.45 /

-0.37 (-0.58%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RDNT RadNet
$18.94 /

-0.05 (-0.26%)

PRTA Prothena
$12.34 /

-0.03 (-0.24%)

OPNT Opiant Pharmaceuticals
$7.78 /

-0.02 (-0.26%)

MRNA Moderna
$93.12 /

-4.88 (-4.98%)

MGLN Magellan Health
$84.72 /

-0.64 (-0.75%)

ITOS iTeos Therapeutics
$23.95 /

-0.08 (-0.33%)

INMD InMode
$42.61 /

+0.8 (+1.91%)

IMGN ImmunoGen
$5.78 /

+0.03 (+0.52%)

FGEN FibroGen
$44.14 /

+1.12 (+2.60%)

ESPR Esperion
$30.13 /

+0.02 (+0.07%)

CRL Charles River
$236.30 /

-1.56 (-0.66%)

CNCE Concert Pharmaceuticals
$11.04 /

+0.03 (+0.27%)

CLBS Caladrius
$1.50 /

-0.005 (-0.33%)

CARA Cara Therapeutics
$16.19 /

+0.5 (+3.19%)

AXGN AxoGen
$15.29 /

+0.18 (+1.19%)

ALNA Allena Pharmaceuticals
$1.43 /

-0.15 (-9.49%)

  • 16
    Sep
  • 24
    Jul
  • 10
    Jul
  • 19
    May
  • 12
    Mar
  • 11
    Feb
  • 12
    Feb
  • 28
    Jan
  • 21
    Jan
RHHBY Roche
$0.00 /

+ (+0.00%)

MRNA Moderna
$93.12 /

-4.88 (-4.98%)

SYNH Syneos Health
$63.45 /

-0.37 (-0.58%)

SMMNY Siemens Healthineers
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

MRNA Moderna
$93.12 /

-4.88 (-4.98%)

IVA Inventiva
$14.00 /

+0.175 (+1.27%)

ITOS iTeos Therapeutics
$23.95 /

-0.08 (-0.33%)

IMGN ImmunoGen
$5.78 /

+0.03 (+0.52%)

FGEN FibroGen
$44.14 /

+1.12 (+2.60%)

ESPR Esperion
$30.13 /

+0.02 (+0.07%)

CARA Cara Therapeutics
$16.19 /

+0.5 (+3.19%)

AXGN AxoGen
$15.29 /

+0.18 (+1.19%)

MRNA Moderna
$93.12 /

-4.88 (-4.98%)

FGEN FibroGen
$44.14 /

+1.12 (+2.60%)

ESPR Esperion
$30.13 /

+0.02 (+0.07%)

Conference/Events
Jefferies to hold a virtual conference » 08:54
11/17/20
11/17
08:54
11/17/20
08:54
MRNA

Moderna

$97.95 /

+8.65 (+9.69%)

, IMGN

ImmunoGen

$5.75 /

-0.1 (-1.71%)

, ESPR

Esperion

$30.11 /

+1.45 (+5.06%)

, CRL

Charles River

$237.94 /

-0.75 (-0.31%)

, AXGN

AxoGen

$15.09 /

+0.445 (+3.04%)

, INMD

InMode

$41.88 /

-0.01 (-0.02%)

, PRTA

Prothena

$12.37 /

+0.07 (+0.57%)

, SYNH

Syneos Health

$63.82 /

+0.48 (+0.76%)

, RDNT

RadNet

$18.99 /

+0.43 (+2.32%)

, OPNT

Opiant Pharmaceuticals

$7.83 /

+0.045 (+0.58%)

, FGEN

FibroGen

$43.03 /

+0.79 (+1.87%)

, MGLN

Magellan Health

$85.23 /

+0.11 (+0.13%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, CARA

Cara Therapeutics

$15.69 /

+0.28 (+1.82%)

, IVA

Inventiva

$14.00 /

-0.005 (-0.04%)

, ITOS

iTeos Therapeutics

$24.03 /

+0.36 (+1.52%)

, CLBS

Caladrius

$1.50 /

-0.01 (-0.66%)

, ALNA

Allena Pharmaceuticals

$1.58 /

+0.07 (+4.64%)

, SEEL

Seelos Therapeutics

$0.82 /

-0.0299 (-3.52%)

, SMMNY

Siemens Healthineers

$0.00 /

+ (+0.00%)

, CNCE

Concert Pharmaceuticals

$11.01 /

-0.05 (-0.45%)

Virtual Healthcare…

Virtual Healthcare Conference will be held on November 17-19.

ShowHide Related Items >><<
SYNH Syneos Health
$63.82 /

+0.48 (+0.76%)

SMMNY Siemens Healthineers
$0.00 /

+ (+0.00%)

SEEL Seelos Therapeutics
$0.82 /

-0.0299 (-3.52%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RDNT RadNet
$18.99 /

+0.43 (+2.32%)

PRTA Prothena
$12.37 /

+0.07 (+0.57%)

OPNT Opiant Pharmaceuticals
$7.83 /

+0.045 (+0.58%)

MRNA Moderna
$97.95 /

+8.65 (+9.69%)

MGLN Magellan Health
$85.23 /

+0.11 (+0.13%)

IVA Inventiva
$14.00 /

-0.005 (-0.04%)

ITOS iTeos Therapeutics
$24.03 /

+0.36 (+1.52%)

INMD InMode
$41.88 /

-0.01 (-0.02%)

IMGN ImmunoGen
$5.75 /

-0.1 (-1.71%)

FGEN FibroGen
$43.03 /

+0.79 (+1.87%)

ESPR Esperion
$30.11 /

+1.45 (+5.06%)

CRL Charles River
$237.94 /

-0.75 (-0.31%)

CNCE Concert Pharmaceuticals
$11.01 /

-0.05 (-0.45%)

CLBS Caladrius
$1.50 /

-0.01 (-0.66%)

CARA Cara Therapeutics
$15.69 /

+0.28 (+1.82%)

AXGN AxoGen
$15.09 /

+0.445 (+3.04%)

ALNA Allena Pharmaceuticals
$1.58 /

+0.07 (+4.64%)

MRNA Moderna
$97.95 /

+8.65 (+9.69%)

11/17/20 Maxim
Co-Diagnostics price target lowered to $20 from $30 at Maxim
11/17/20 Roth Capital
Inovio downgraded to Sell at Roth Capital on increased competition
11/17/20 Redburn
Moderna initiated with a Sell at Redburn
11/17/20 BMO Capital
Moderna downgraded to Market Perform from Outperform at BMO Capital
IMGN ImmunoGen
$5.75 /

-0.1 (-1.71%)

10/26/20 H.C. Wainwright
ImmunoGen assumed with a Buy at H.C. Wainwright
10/19/20 Piper Sandler
Greater China partnership 'very favorable' for ImmunoGen, says Piper Sandler
10/05/20 Piper Sandler
Piper says r/r BPDCN revenue opportunity for ImmunoGen's 632 'an open question'
10/02/20 Guggenheim
ImmunoGen upgraded to Buy from Neutral at Guggenheim
ESPR Esperion
$30.11 /

+1.45 (+5.06%)

11/10/20 Credit Suisse
Esperion upgraded to Outperform from Neutral at Credit Suisse
09/29/20 JPMorgan
Esperion resumed with an Underweight at JPMorgan
08/10/20 Credit Suisse
Esperion downgraded to Neutral from Outperform at Credit Suisse
05/07/20 Citi
Esperion price target raised to $56 from $46 at Citi
CRL Charles River
$237.94 /

-0.75 (-0.31%)

11/03/20 Truist
Charles River price target raised to $256 from $237 at Truist
10/30/20 Deutsche Bank
Charles River price target raised to $250 from $235 at Deutsche Bank
09/14/20 Argus
Charles River price target raised to $235 from $190 at Argus
09/10/20
Fly Intel: Top five analyst upgrades
AXGN AxoGen
$15.09 /

+0.445 (+3.04%)

10/22/20 Guggenheim
AxoGen initiated with a Buy at Guggenheim
06/16/20 Cantor Fitzgerald
AxoGen assumed with an Overweight at Cantor Fitzgerald
06/15/20 Cantor Fitzgerald
AxoGen assumed with an Overweight at Cantor Fitzgerald
05/07/20 Canaccord
AxoGen downgraded to Hold at Canaccord
INMD InMode
$41.88 /

-0.01 (-0.02%)

10/21/20 Canaccord
InMode price target raised to $51 from $42 at Canaccord
10/13/20 Baird
InMode price target raised to $55 from $43 at Baird
02/19/20 Barclays
InMode price target raised to $48 from $45 at Barclays
01/28/20 Baird
InMode price target raised to $55 from $45 at Baird
PRTA Prothena
$12.37 /

+0.07 (+0.57%)

10/21/20 Cantor Fitzgerald
Prothena price target raised to $24 from $20 at Cantor Fitzgerald
07/09/20 Oppenheimer
Prothena upgraded to Outperform at Oppenheimer
07/09/20 Oppenheimer
Prothena upgraded to Outperform from Perform at Oppenheimer
11/19/19 Evercore ISI
Prothena upgraded to Outperform on valuation at Evercore ISI
SYNH Syneos Health
$63.82 /

+0.48 (+0.76%)

10/06/20 Mizuho
Syneos Health upgraded to Buy on attractive entry point at Mizuho
10/06/20 Mizuho
Syneos Health upgraded to Buy from Neutral at Mizuho
10/01/20 Goldman Sachs
Syneos Health upgraded to Buy from Neutral at Goldman Sachs
08/12/20 Truist
Syneos Health price target raised to $80 from $74 at Truist
RDNT RadNet
$18.99 /

+0.43 (+2.32%)

09/03/20 Clarus
Akumin can re-rate as Nasdaq listing raises U.S. awareness, says Clarus
OPNT Opiant Pharmaceuticals
$7.83 /

+0.045 (+0.58%)

FGEN FibroGen
$43.03 /

+0.79 (+1.87%)

10/26/20 Raymond James
FibroGen initiated with an Underperform at Raymond James
10/26/20 Raymond James
FibroGen initiated with an Underperform at Raymond James
10/23/20 Stifel
FibroGen safety data mitigates concerns of roxadustat black box, says Stifel
09/04/20 Stifel
FibroGen's roxadustat can be 'dominant leader' as competitor fades, says Stifel
MGLN Magellan Health
$85.23 /

+0.11 (+0.13%)

11/13/20
Fly Intel: Top five analyst upgrades
11/13/20 Stephens
Magellan Health upgraded to Overweight from Equal Weight at Stephens
RHHBY Roche
$0.00 /

+ (+0.00%)

11/11/20 Truist
Opthea initiated with a Buy at Truist
10/16/20 UBS
Roche price target lowered to CHF 370 from CHF 390 at UBS
10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
09/29/20 Berenberg
Roche initiated with a Hold at Berenberg
CARA Cara Therapeutics
$15.69 /

+0.28 (+1.82%)

10/20/20 H.C. Wainwright
Cara deal with 'perfect partner' Vifor boosts confidence at H.C. Wainwright
04/22/20 Cantor Fitzgerald
Cara Therapeutics price target raised to $34 from $26 at Cantor Fitzgerald
04/21/20 H.C. Wainwright
Cara Therapeutics price target raised to $33 from $30 at H.C. Wainwright
01/10/20 Stifel
Cara Therapeutics named a BioPharma top pick for 2020 at Stifel
IVA Inventiva
$14.00 /

-0.005 (-0.04%)

10/13/20 Roth Capital
Roth backs Buy on Inventiva after Lanifibranor given breakthrough designation
08/17/20 H.C. Wainwright
Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright
08/05/20
Fly Intel: Top five analyst initiations
08/05/20 Roth Capital
Inventiva initiated with a Buy at Roth Capital
ITOS iTeos Therapeutics
$24.03 /

+0.36 (+1.52%)

10/07/20 Baird
iTeos Therapeutics initiated with an Outperform at Baird
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
09/01/20 Piper Sandler
iTeos Therapeutics heading for 'catalyst rich stretch', says Piper Sandler
08/18/20 SVB Leerink
SVB Leerink bullish on iTeos Therapeutics, initiates with an Outperform
CLBS Caladrius
$1.50 /

-0.01 (-0.66%)

05/22/20 Brookline
Caladrius initiated with a Buy at Brookline
05/18/20 Dawson James
Caladrius downgraded to Neutral from Buy at Dawson James
ALNA Allena Pharmaceuticals
$1.58 /

+0.07 (+4.64%)

10/01/20 B. Riley Securities
Allena Pharmaceuticals price target raised to $5 from $4 at B. Riley Securities
06/01/20 H.C. Wainwright
Allena Pharmaceuticals initiated with a Buy at H.C. Wainwright
03/18/20 Roth Capital
Allena Pharmaceuticals price target lowered to $11 from $31 at Roth Capital
02/12/20 Roth Capital
Streamlining makes Allena URIROX-2 path clear, says Roth Capital
SEEL Seelos Therapeutics
$0.82 /

-0.0299 (-3.52%)

09/09/20 Roth Capital
Seelos Therapeutics shares 'substantially undervalued,' says Roth Capital
06/23/20 Roth Capital
Seelos Therapeutics price target raised to $12 from $8 Roth Capital
11/18/19 H.C. Wainwright
Seelos Therapeutics price target lowered to $2 from $4 at H.C. Wainwright
SMMNY Siemens Healthineers
$0.00 /

+ (+0.00%)

11/10/20 Credit Suisse
Siemens Healthineers price target raised to EUR 44 from EUR 43 at Credit Suisse
10/28/20 Barrington
Varian Medical downgraded to Underperform from Outperform at Barrington
10/26/20 RBC Capital
Siemens Healthineers price target lowered to EUR 42 from EUR 45 at RBC Capital
10/06/20 Deutsche Bank
Siemens Healthineers price target lowered to EUR 39 at Deutsche Bank
CNCE Concert Pharmaceuticals
$11.01 /

-0.05 (-0.45%)

11/04/20 JMP Securities
Concert Pharmaceuticals resumed with an Outperform at JMP Securities
03/30/20
Fly Intel: Top five analyst initiations
03/30/20 Jefferies
Concert Pharmaceuticals initiated with a Buy at Jefferies
02/27/20 Stifel
Concert Pharmaceuticals price target raised to $11 from $8 at Stifel
SYNH Syneos Health
$63.82 /

+0.48 (+0.76%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RDNT RadNet
$18.99 /

+0.43 (+2.32%)

PRTA Prothena
$12.37 /

+0.07 (+0.57%)

OPNT Opiant Pharmaceuticals
$7.83 /

+0.045 (+0.58%)

MRNA Moderna
$97.95 /

+8.65 (+9.69%)

MGLN Magellan Health
$85.23 /

+0.11 (+0.13%)

ITOS iTeos Therapeutics
$24.03 /

+0.36 (+1.52%)

INMD InMode
$41.88 /

-0.01 (-0.02%)

IMGN ImmunoGen
$5.75 /

-0.1 (-1.71%)

FGEN FibroGen
$43.03 /

+0.79 (+1.87%)

ESPR Esperion
$30.11 /

+1.45 (+5.06%)

CRL Charles River
$237.94 /

-0.75 (-0.31%)

CNCE Concert Pharmaceuticals
$11.01 /

-0.05 (-0.45%)

CLBS Caladrius
$1.50 /

-0.01 (-0.66%)

CARA Cara Therapeutics
$15.69 /

+0.28 (+1.82%)

AXGN AxoGen
$15.09 /

+0.445 (+3.04%)

ALNA Allena Pharmaceuticals
$1.58 /

+0.07 (+4.64%)

  • 16
    Sep
  • 24
    Jul
  • 10
    Jul
  • 19
    May
  • 12
    Mar
  • 11
    Feb
  • 12
    Feb
  • 28
    Jan
  • 21
    Jan
RHHBY Roche
$0.00 /

+ (+0.00%)

MRNA Moderna
$97.95 /

+8.65 (+9.69%)

SYNH Syneos Health
$63.82 /

+0.48 (+0.76%)

SMMNY Siemens Healthineers
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

MRNA Moderna
$97.95 /

+8.65 (+9.69%)

IVA Inventiva
$14.00 /

-0.005 (-0.04%)

ITOS iTeos Therapeutics
$24.03 /

+0.36 (+1.52%)

IMGN ImmunoGen
$5.75 /

-0.1 (-1.71%)

FGEN FibroGen
$43.03 /

+0.79 (+1.87%)

ESPR Esperion
$30.11 /

+1.45 (+5.06%)

CARA Cara Therapeutics
$15.69 /

+0.28 (+1.82%)

AXGN AxoGen
$15.09 /

+0.445 (+3.04%)

MRNA Moderna
$97.95 /

+8.65 (+9.69%)

FGEN FibroGen
$43.03 /

+0.79 (+1.87%)

ESPR Esperion
$30.11 /

+1.45 (+5.06%)

Over a month ago
Earnings
AxoGen reports Q3 EPS 4c, consensus (14c) » 16:07
10/29/20
10/29
16:07
10/29/20
16:07
AXGN

AxoGen

$12.80 /

+0.59 (+4.83%)

Reports Q3 revenue…

Reports Q3 revenue $33.4M, consensus $27.37M.

ShowHide Related Items >><<
AXGN AxoGen
$12.80 /

+0.59 (+4.83%)

AXGN AxoGen
$12.80 /

+0.59 (+4.83%)

10/22/20 Guggenheim
AxoGen initiated with a Buy at Guggenheim
06/16/20 Cantor Fitzgerald
AxoGen assumed with an Overweight at Cantor Fitzgerald
06/15/20 Cantor Fitzgerald
AxoGen assumed with an Overweight at Cantor Fitzgerald
05/07/20 Canaccord
AxoGen downgraded to Hold at Canaccord
AXGN AxoGen
$12.80 /

+0.59 (+4.83%)

AXGN AxoGen
$12.80 /

+0.59 (+4.83%)

Initiation
AxoGen initiated with a Buy at Guggenheim » 16:19
10/22/20
10/22
16:19
10/22/20
16:19
AXGN

AxoGen

$13.35 /

+0.23 (+1.75%)

Guggenheim analyst Chris…

Guggenheim analyst Chris Pasquale initiated coverage of AxoGen with a Buy rating and $24 price target.

ShowHide Related Items >><<
AXGN AxoGen
$13.35 /

+0.23 (+1.75%)

AXGN AxoGen
$13.35 /

+0.23 (+1.75%)

06/16/20 Cantor Fitzgerald
AxoGen assumed with an Overweight at Cantor Fitzgerald
06/15/20 Cantor Fitzgerald
AxoGen assumed with an Overweight at Cantor Fitzgerald
05/07/20 Canaccord
AxoGen downgraded to Hold at Canaccord
05/07/20 Canaccord
AxoGen downgraded to Hold from Buy at Canaccord
AXGN AxoGen
$13.35 /

+0.23 (+1.75%)

AXGN AxoGen
$13.35 /

+0.23 (+1.75%)

Over a quarter ago
Conference/Events
AxoGen management to meet virtually with JMP Securities » 08:36
08/13/20
08/13
08:36
08/13/20
08:36
AXGN

AxoGen

$11.27 /

-0.05 (-0.44%)

Virtual Meeting to be…

Virtual Meeting to be held on August 13 hosted by JMP Securities.

ShowHide Related Items >><<
AXGN AxoGen
$11.27 /

-0.05 (-0.44%)

AXGN AxoGen
$11.27 /

-0.05 (-0.44%)

06/16/20 Cantor Fitzgerald
AxoGen assumed with an Overweight at Cantor Fitzgerald
06/15/20 Cantor Fitzgerald
AxoGen assumed with an Overweight at Cantor Fitzgerald
05/07/20 Canaccord
AxoGen downgraded to Hold at Canaccord
05/07/20 Canaccord
AxoGen downgraded to Hold from Buy at Canaccord
AXGN AxoGen
$11.27 /

-0.05 (-0.44%)

AXGN AxoGen
$11.27 /

-0.05 (-0.44%)

Earnings
AxoGen reports Q2 EPS (20c), consensus (38c) » 16:25
08/05/20
08/05
16:25
08/05/20
16:25
AXGN

AxoGen

$12.30 /

+0.31 (+2.59%)

Reports Q2 revenue…

Reports Q2 revenue $22.1M, consensus $13.15M. "We are encouraged by the performance of our commercial team and the demand for our products over the course of the quarter as surgery schedules opened and hospitals quickly moved to complete nerve repair procedures," commented Karen Zaderej, chairman, CEO, and president of Axogen. "We expect that most deferred nerve repair procedures will be scheduled by the end of the summer and believe that regional COVID-19 resurgence may continue to negatively impact the incidence of trauma and surgical procedure volumes in certain geographies. As a result, we remain measured in our outlook for the remainder of the year and expect that revenue in the third and fourth quarters will continue to trend below prior-year results. However, we are pleased with the resilience we have seen with our business and we believe that the strength of our balance sheet, along with our cost mitigation initiatives, will allow us to emerge from this pandemic-related downturn as a stronger, leaner organization on a path to profitability."

ShowHide Related Items >><<
AXGN AxoGen
$12.30 /

+0.31 (+2.59%)

AXGN AxoGen
$12.30 /

+0.31 (+2.59%)

06/16/20 Cantor Fitzgerald
AxoGen assumed with an Overweight at Cantor Fitzgerald
06/15/20 Cantor Fitzgerald
AxoGen assumed with an Overweight at Cantor Fitzgerald
05/07/20 Canaccord
AxoGen downgraded to Hold at Canaccord
05/07/20 Canaccord
AxoGen downgraded to Hold from Buy at Canaccord
AXGN AxoGen
$12.30 /

+0.31 (+2.59%)

AXGN AxoGen
$12.30 /

+0.31 (+2.59%)

Hot Stocks
AxoGen RECON study completes target enrollment of 220 subjects » 07:14
07/22/20
07/22
07:14
07/22/20
07:14
AXGN

AxoGen

$12.08 /

+0.21 (+1.77%)

Axogen announced that its…

Axogen announced that its phase 3 pivotal RECONSM Clinical Study supporting its Biologics License Application submission for Avance Nerve Graft has reached its enrollment target of 220 subjects. RECON compares Avance Nerve Graft to manufactured conduits in digital nerve injuries with a primary endpoint of return of sensation and secondary endpoints for quality of life and patient satisfaction. The RECON Clinical Study protocol requires a one-year follow-up assessment with an additional three month visit window. With the final subject enrolled in July of 2020, the last patient is expected to complete the study no later than October of 2021. The company anticipates it will provide a preliminary report of trial data in the second quarter of 2022 and expects to file the BLA in 2023.

ShowHide Related Items >><<
AXGN AxoGen
$12.08 /

+0.21 (+1.77%)

AXGN AxoGen
$12.08 /

+0.21 (+1.77%)

06/16/20 Cantor Fitzgerald
AxoGen assumed with an Overweight at Cantor Fitzgerald
06/15/20 Cantor Fitzgerald
AxoGen assumed with an Overweight at Cantor Fitzgerald
05/07/20 Canaccord
AxoGen downgraded to Hold at Canaccord
05/07/20 Canaccord
AxoGen downgraded to Hold from Buy at Canaccord
AXGN AxoGen
$12.08 /

+0.21 (+1.77%)

AXGN AxoGen
$12.08 /

+0.21 (+1.77%)

On The Fly
Fly Intel: Wall Street's top stories for Wednesday » 16:27
07/01/20
07/01
16:27
07/01/20
16:27
PFE

Pfizer

$33.75 /

+1.06 (+3.24%)

, BNTX

BioNTech

$64.14 /

-2.595 (-3.89%)

, FDX

FedEx

$156.86 /

+16.61 (+11.84%)

, STZ

Constellation Brands

$185.85 /

+11.415 (+6.54%)

, GM

General Motors

$24.95 /

-0.35 (-1.38%)

, FCAU

Fiat Chrysler

$9.90 /

-0.345 (-3.37%)

, VWAGY

Volkswagen

$0.00 /

+ (+0.00%)

, HMC

Honda

$25.37 /

-0.19 (-0.74%)

, AAPL

Apple

$364.11 /

-0.35 (-0.10%)

, AKRO

Akero Therapeutics

$33.50 /

+8.65 (+34.81%)

, AXGN

AxoGen

$11.74 /

+2.48 (+26.78%)

, INO

Inovio

$19.73 /

-7.15 (-26.60%)

, SCS

Steelcase

$10.38 /

-1.69 (-14.00%)

The S&P began the third…

ShowHide Related Items >><<
VWAGY Volkswagen
$0.00 /

+ (+0.00%)

STZ Constellation Brands
$185.85 /

+11.415 (+6.54%)

SCS Steelcase
$10.38 /

-1.69 (-14.00%)

PFE Pfizer
$33.75 /

+1.06 (+3.24%)

INO Inovio
$19.73 /

-7.15 (-26.60%)

HMC Honda
$25.37 /

-0.19 (-0.74%)

GM General Motors
$24.95 /

-0.35 (-1.38%)

FDX FedEx
$156.86 /

+16.61 (+11.84%)

FCAU Fiat Chrysler
$9.90 /

-0.345 (-3.37%)

AXGN AxoGen
$11.74 /

+2.48 (+26.78%)

AKRO Akero Therapeutics
$33.50 /

+8.65 (+34.81%)

AAPL Apple
$364.11 /

-0.35 (-0.10%)

PFE Pfizer
$33.75 /

+1.06 (+3.24%)

07/01/20 Goldman Sachs
Pfizer COVID-19 vaccine data 'encouraging,' says Goldman Sachs
06/30/20 H.C. Wainwright
BioNTech downgraded to Neutral from Buy at H.C. Wainwright
06/29/20 Mizuho
Pfizer resumed with a Buy at Mizuho
06/25/20 Piper Sandler
Aptevo Therapeutics price target raised to $24 from $18.50 at Piper Sandler
BNTX BioNTech
$64.14 /

-2.595 (-3.89%)

07/02/20 Bryan Garnier
BioNTech price target raised to $62.50 from $50 at Bryan Garnier
06/25/20 H.C. Wainwright
BioNTech price target lowered to $63 from $69 at H.C. Wainwright
FDX FedEx
$156.86 /

+16.61 (+11.84%)

07/01/20
Fly Intel: Top five analyst upgrades
07/01/20 Cowen
FedEx price target raised to $167 from $156 at Cowen
07/01/20 Wells Fargo
FedEx price target raised to $179 from $153 at Wells Fargo
07/01/20 Baird
FedEx price target raised to $162 from $140 at Baird
STZ Constellation Brands
$185.85 /

+11.415 (+6.54%)

07/02/20 UBS
Constellation Brands price target raised to $208 from $192 at UBS
07/02/20 Jefferies
Constellation Brands price target raised to $238 from $224 at Jefferies
07/02/20 Citi
Constellation Brands price target raised to $200 from $176 at Citi
07/02/20 HSBC
Constellation Brands price target raised to $170 from $147 at HSBC
GM General Motors
$24.95 /

-0.35 (-1.38%)

06/25/20 Morgan Stanley
Talks with Ford dealer highlight inventory risk, says Morgan Stanley
06/24/20 Morgan Stanley
GM electric vehicle business could be worth $100B, says Morgan Stanley
06/19/20 JPMorgan
General Motors price target raised to $33 from $29 at JPMorgan
06/18/20 Jefferies
Jefferies raises price targets for Ford, GM and FCA on balance sheet de-risking
FCAU Fiat Chrysler
$9.90 /

-0.345 (-3.37%)

06/30/20 UBS
Fiat Chrysler price target raised to EUR 9 from EUR 6 at UBS
06/22/20 Redburn
Fiat Chrysler upgraded to Buy from Neutral at Redburn
VWAGY Volkswagen
$0.00 /

+ (+0.00%)

06/30/20 UBS
Volkswagen price target raised to EUR 180 from EUR 140 at UBS
06/18/20 Jefferies
Volkswagen price target raised to EUR 135 from EUR 115 at Jefferies
06/16/20 BofA
Volkswagen downgraded to Neutral from Buy at BofA
HMC Honda
$25.37 /

-0.19 (-0.74%)

05/12/20 CLSA
Honda downgraded to Underperform from Outperform at CLSA
04/13/20 Goldman Sachs
Honda upgraded to Buy from Neutral at Goldman Sachs
03/30/20 UBS
Toyota and Honda upgraded to Buy, Nissan cut to Sell at UBS
AAPL Apple
$364.11 /

-0.35 (-0.10%)

06/26/20 Evercore ISI
Evercore upgrades Broadcom to Outperform, sees Apple sales driving upside
06/25/20 Wedbush
Wedbush boosts Apple target to $425, sees $2 trillion valuation in 2021
06/24/20 BMO Capital
Criteo downgraded to Market Perform from Outperform at BMO Capital
06/23/20 Baird
Apple price target raised to $390 from $320 at Baird
AKRO Akero Therapeutics
$33.50 /

+8.65 (+34.81%)

07/01/20 JPMorgan
Akero Therapeutics price target raised to $41 from $28 at JPMorgan
07/01/20 Jefferies
Akero Therapeutics price target raised to $48 from $31 at Jefferies
07/01/20 Canaccord
Akero Therapeutics price target raised to $51 from $36 at Canaccord
07/01/20 H.C. Wainwright
Akero Therapeutics price target raised to $45 from $33 at H.C. Wainwright
AXGN AxoGen
$11.74 /

+2.48 (+26.78%)

06/16/20 Cantor Fitzgerald
AxoGen assumed with an Overweight at Cantor Fitzgerald
06/15/20 Cantor Fitzgerald
AxoGen assumed with an Overweight at Cantor Fitzgerald
05/07/20 Canaccord
AxoGen downgraded to Hold at Canaccord
05/07/20 Canaccord
AxoGen downgraded to Hold from Buy at Canaccord
INO Inovio
$19.73 /

-7.15 (-26.60%)

07/01/20
Fly Intel: Top five analyst downgrades
07/01/20 Maxim
Inovio downgraded to Hold from Buy at Maxim
07/01/20 Roth Capital
Roth 'unimpressed' with Inovio data, downgrades to Sell with $11 target
07/01/20 Maxim
Inovio downgraded to Hold from Buy at Maxim
SCS Steelcase
$10.38 /

-1.69 (-14.00%)

05/22/20 Benchmark
Steelcase initiated with a Buy at Benchmark
10/07/19 Raymond James
Raymond James steps away from three office furniture stocks
10/07/19 Raymond James
Steelcase downgraded to Market Perform from Strong Buy at Raymond James
09/23/19 Raymond James
Steelcase price target raised to $23 from $21 at Raymond James
VWAGY Volkswagen
$0.00 /

+ (+0.00%)

STZ Constellation Brands
$185.85 /

+11.415 (+6.54%)

SCS Steelcase
$10.38 /

-1.69 (-14.00%)

PFE Pfizer
$33.75 /

+1.06 (+3.24%)

INO Inovio
$19.73 /

-7.15 (-26.60%)

HMC Honda
$25.37 /

-0.19 (-0.74%)

GM General Motors
$24.95 /

-0.35 (-1.38%)

FDX FedEx
$156.86 /

+16.61 (+11.84%)

FCAU Fiat Chrysler
$9.90 /

-0.345 (-3.37%)

BNTX BioNTech
$64.14 /

-2.595 (-3.89%)

AXGN AxoGen
$11.74 /

+2.48 (+26.78%)

AKRO Akero Therapeutics
$33.50 /

+8.65 (+34.81%)

AAPL Apple
$364.11 /

-0.35 (-0.10%)

  • 06
    Feb
  • 10
    Oct
VWAGY Volkswagen
$0.00 /

+ (+0.00%)

STZ Constellation Brands
$185.85 /

+11.415 (+6.54%)

PFE Pfizer
$33.75 /

+1.06 (+3.24%)

INO Inovio
$19.73 /

-7.15 (-26.60%)

HMC Honda
$25.37 /

-0.19 (-0.74%)

GM General Motors
$24.95 /

-0.35 (-1.38%)

FDX FedEx
$156.86 /

+16.61 (+11.84%)

FCAU Fiat Chrysler
$9.90 /

-0.345 (-3.37%)

AAPL Apple
$364.11 /

-0.35 (-0.10%)

VWAGY Volkswagen
$0.00 /

+ (+0.00%)

STZ Constellation Brands
$185.85 /

+11.415 (+6.54%)

PFE Pfizer
$33.75 /

+1.06 (+3.24%)

GM General Motors
$24.95 /

-0.35 (-1.38%)

FDX FedEx
$156.86 /

+16.61 (+11.84%)

FCAU Fiat Chrysler
$9.90 /

-0.345 (-3.37%)

BNTX BioNTech
$64.14 /

-2.595 (-3.89%)

AKRO Akero Therapeutics
$33.50 /

+8.65 (+34.81%)

AAPL Apple
$364.11 /

-0.35 (-0.10%)

FDX FedEx
$156.86 /

+16.61 (+11.84%)

STZ Constellation Brands
$185.85 /

+11.415 (+6.54%)

SCS Steelcase
$10.38 /

-1.69 (-14.00%)

PFE Pfizer
$33.75 /

+1.06 (+3.24%)

INO Inovio
$19.73 /

-7.15 (-26.60%)

GM General Motors
$24.95 /

-0.35 (-1.38%)

FDX FedEx
$156.86 /

+16.61 (+11.84%)

FCAU Fiat Chrysler
$9.90 /

-0.345 (-3.37%)

BNTX BioNTech
$64.14 /

-2.595 (-3.89%)

AKRO Akero Therapeutics
$33.50 /

+8.65 (+34.81%)

AAPL Apple
$364.11 /

-0.35 (-0.10%)

AAPL Apple
$364.11 /

-0.35 (-0.10%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.